News on Drug Discovery Limited from BioPortfolio.com http://www.BioPortfolio.com Consolidated Drug Discovery Limited news from BioPortfolio.com Wed, 10 Feb 2010 14:20:25 GMT en Article: The 21st Century Model Of Drug Discoveryhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4039664&HITNO=0&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Drug%20Discovery%20Limited&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4039664&THISHREF=http://c.moreover.com/click/here.pl%3fz2538308008%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4039664&HITNO=0&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Drug%20Discovery%20Limited&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4039664&THISHREF=http://c.moreover.com/click/here.pl%3fz2538308008%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comDrug Discovery Online: Ligon Discovery, Lycera announce collaboration to identify drug candidates for immune disordershttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4039808&HITNO=1&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Drug%20Discovery%20Limited&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4039808&THISHREF=http://c.moreover.com/click/here.pl%3fz2538390058%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4039808&HITNO=1&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Drug%20Discovery%20Limited&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4039808&THISHREF=http://c.moreover.com/click/here.pl%3fz2538390058%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comNews-Medical.Net: HDAC Inhibitors in Cancer Carehttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4040995&HITNO=2&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Drug%20Discovery%20Limited&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4040995&THISHREF=http://c.moreover.com/click/here.pl%3fz2538960022%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4040995&HITNO=2&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Drug%20Discovery%20Limited&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4040995&THISHREF=http://c.moreover.com/click/here.pl%3fz2538960022%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comConsultant Live: MDS (MDZ) to Receive About $45M to Divest Pharma Services Early Stage Bizhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4041929&HITNO=3&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Drug%20Discovery%20Limited&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4041929&THISHREF=http://c.moreover.com/click/here.pl%3fz2539258061%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4041929&HITNO=3&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Drug%20Discovery%20Limited&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4041929&THISHREF=http://c.moreover.com/click/here.pl%3fz2539258061%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comStreet Insider: MDS to divest remaining MDS Pharma Services Early Stage business for $45Mhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4041912&HITNO=4&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Drug%20Discovery%20Limited&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4041912&THISHREF=http://c.moreover.com/click/here.pl%3fz2539253042%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4041912&HITNO=4&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Drug%20Discovery%20Limited&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4041912&THISHREF=http://c.moreover.com/click/here.pl%3fz2539253042%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comNews-Medical.Net: MDS Announces Agreements to Divest MDS Pharma Services' Early Stage Business / Company Focused on Building MDS Nordionhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4041487&HITNO=5&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Drug%20Discovery%20Limited&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4041487&THISHREF=http://c.moreover.com/click/here.pl%3fz2539149354%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4041487&HITNO=5&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Drug%20Discovery%20Limited&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4041487&THISHREF=http://c.moreover.com/click/here.pl%3fz2539149354%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comFinanzNachrichten.de: MDS Announces Agreements to Divest MDS Pharma Services' Early Stage Businesshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4042029&HITNO=6&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Drug%20Discovery%20Limited&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4042029&THISHREF=http://c.moreover.com/click/here.pl%3fz2539283129%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4042029&HITNO=6&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Drug%20Discovery%20Limited&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4042029&THISHREF=http://c.moreover.com/click/here.pl%3fz2539283129%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comInterest!ALERT: Daiichi Sankyo's subsidiary seeks approval for Alzheimer's type Dementia treatment in Japanhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4039734&HITNO=7&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Drug%20Discovery%20Limited&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4039734&THISHREF=http://c.moreover.com/click/here.pl%3fz2538348937%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4039734&HITNO=7&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Drug%20Discovery%20Limited&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4039734&THISHREF=http://c.moreover.com/click/here.pl%3fz2538348937%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comTherapeutics Daily: Infosys Technologies and Elan Pharmaceuticals Apply Co-creation Model to Transform Discovery Research 2/5/10http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4036664&HITNO=8&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Drug%20Discovery%20Limited&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4036664&THISHREF=http://c.moreover.com/click/here.pl%3fz2536699449%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4036664&HITNO=8&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Drug%20Discovery%20Limited&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4036664&THISHREF=http://c.moreover.com/click/here.pl%3fz2536699449%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comAmerican Pharmaceutical Outsourcing: Drug Discovery In India and China Gaining Momentum with Increasing Pressure on Cost Cuttinghttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034581&HITNO=9&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Drug%20Discovery%20Limited&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034581&THISHREF=http://c.moreover.com/click/here.pl%3fz2535872288%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034581&HITNO=9&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Drug%20Discovery%20Limited&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034581&THISHREF=http://c.moreover.com/click/here.pl%3fz2535872288%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comYour Story: Ligon Discovery and Lycera Collaborate to Develop First-in-Class Drugs for Immune Disordershttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4037759&HITNO=10&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Drug%20Discovery%20Limited&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4037759&THISHREF=http://c.moreover.com/click/here.pl%3fz2537270863%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4037759&HITNO=10&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Drug%20Discovery%20Limited&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4037759&THISHREF=http://c.moreover.com/click/here.pl%3fz2537270863%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comYahoo! Canada: Ligon Discovery and Lycera Collaborate to Develop First-in-Class Drugs for Immune Disordershttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4037547&HITNO=11&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Drug%20Discovery%20Limited&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4037547&THISHREF=http://c.moreover.com/click/here.pl%3fz2537138965%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4037547&HITNO=11&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Drug%20Discovery%20Limited&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4037547&THISHREF=http://c.moreover.com/click/here.pl%3fz2537138965%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharma Live: Ligon Discovery and Lycera Collaborate to Develop First-in-Class Drugs for Immune Disordershttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4037588&HITNO=12&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Drug%20Discovery%20Limited&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4037588&THISHREF=http://c.moreover.com/click/here.pl%3fz2537162932%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4037588&HITNO=12&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Drug%20Discovery%20Limited&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4037588&THISHREF=http://c.moreover.com/click/here.pl%3fz2537162932%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comTherapeutics Daily: Targacept receives grant for developing alpha6*-selective NNR Imaging Agent as Parkinsons disease biomarkerhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034239&HITNO=13&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Drug%20Discovery%20Limited&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034239&THISHREF=http://c.moreover.com/click/here.pl%3fz2535687055%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034239&HITNO=13&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Drug%20Discovery%20Limited&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034239&THISHREF=http://c.moreover.com/click/here.pl%3fz2535687055%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comNews-Medical.Net: Targacept Awarded a Grant from The Michael J. Fox Foundation to Conduct Biomarker Research for Parkinson's Dishttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033208&HITNO=14&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Drug%20Discovery%20Limited&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033208&THISHREF=http://c.moreover.com/click/here.pl%3fz2535065932%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033208&HITNO=14&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Drug%20Discovery%20Limited&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033208&THISHREF=http://c.moreover.com/click/here.pl%3fz2535065932%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharma Live: